Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + Topotecan in Advanced Ovarian Cancer
NCT00179712Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in ovarian cancer and primary peritoneal carcinoma (PPC), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose, Safety Profile and 1 more. Started Apr 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00179712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179712.